J. Chodakewitz

发表

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

J. Mellors, J. Condra, W. Schleif, 1996, Journal of virology.

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Devan V Mehrotra, Ann Duerr, Peter B Gilbert, 2008, The Lancet.

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.

E A Emini, D. Richman, D. Havlir, 1997, The New England journal of medicine.

Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.

J. Chodakewitz, J. Wagner, R. Krishna, 2009, British journal of clinical pharmacology.

Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort

J. Chodakewitz, D. Denning, A. Saah, 2010, European Journal of Clinical Microbiology & Infectious Diseases.

Effect of Low‐, Moderate‐, and High‐Fat Meals on Raltegravir Pharmacokinetics

J. Chodakewitz, J. Wagner, D. Brainard, 2011, Journal of clinical pharmacology.

Effect of Telcagepant on Spontaneous Ischemia in Cardiovascular Patients in a Randomized Study

J. Chodakewitz, J. Palcza, R. Blanchard, 2011, Headache.

Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans

J. Chodakewitz, D. Dean, Sanjeev Kumar, 2010, Xenobiotica; the fate of foreign compounds in biological systems.

Safety and tolerability of caspofungin acetate in the treatment of fungal infections

J. Chodakewitz, C. Sable, M. Dinubile, 2002, Transplant infectious disease : an official journal of the Transplantation Society.

Pharmacokinetics, Safety, and Tolerability of Phentermine in Healthy Participants Receiving Taranabant, a Novel Cannabinoid‐1 Receptor (CB1R) Inverse Agonist

J. Chodakewitz, J. Wagner, P. Jumes, 2009, Journal of clinical pharmacology.

Advances in antifungal therapy.

J. Chodakewitz, C. Sable, K. Strohmaier, 2008, Annual review of medicine.

Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A

G. Papanicolaou, J. Chodakewitz, K. Marr, 2004, Transplant infectious disease : an official journal of the Transplantation Society.

Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases.

J. Chodakewitz, M. Lyagoubi, A. Datry, 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up.

D. Richman, D. Havlir, J. Mellors, 1998, JAMA.

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

M A Fischl, M D Hughes, S. Hammer, 1997, The New England journal of medicine.

Septic arthritis and osteomyelitis from a cat bite.

J. Chodakewitz, F. Bia, 1988, The Yale journal of biology and medicine.

Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir

J. Chodakewitz, J. Wagner, T. Marbury, 2009, Antimicrobial Agents and Chemotherapy.

3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine

J. Mellors, J. Condra, J. Chodakewitz, 2000, Annals of Internal Medicine.

Ivermectin and lymphatic filariasis: a clinical update

J. Chodakewitz, 1995 .

Tolerance and efficacy of single high-dose ivermectin for the treatment of loiasis.

J. Chodakewitz, M. Pinder, P. Tshipamba, 1993, The American journal of tropical medicine and hygiene.

Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine

J. Gallant, D. Mehrotra, D. Haas, 2000, AIDS.

Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.

L. Markson, J. Mellors, E. Dasbach, 1999, AIDS research and human retroviruses.

A Randomized, Placebo‐Controlled Study of the Effects of Telcagepant on Exercise Time in Patients With Stable Angina

B. Chaitman, J. Chodakewitz, T. Ho, 2012, Clinical pharmacology and therapeutics.

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

John A Wagner, Rajesh Krishna, Arthur J Bergman, 2007, The Lancet.

Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine

D. Richman, D. Havlir, J. Mellors, 2003, AIDS.

Apparent renin activity following trypsin activation of rat plasma : biochemical and hemodynamic properties

J. Chodakewitz, 1981 .

Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.

C. Lines, J. Chodakewitz, Junshui Ma, 2013, Sleep.

Effect of Different Durations and Formulations of Diltiazem on the Single‐Dose Pharmacokinetics of Midazolam: How Long Do We Go?

John A Wagner, Arthur J Bergman, J. Chodakewitz, 2011, Journal of clinical pharmacology.

Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects

J. Chodakewitz, W. Kraft, J. Wagner, 2010, Platelets.

Human Abuse Potential and Cognitive Effects of Taranabant, a Cannabinoid 1 Receptor Inverse Agonist: A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Study in Recreational Polydrug Users

E. Sellers, J. Chodakewitz, J. Wagner, 2012, Journal of clinical psychopharmacology.

Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables.

J. Bilello, J. Condra, P. Deutsch, 1998, The Journal of infectious diseases.

Abstract #3604: A phase I single-rising dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral akt inhibitor in healthy male volunteers

J. Chodakewitz, J. Wagner, M. Trucksis, 2009 .

Effect of Different Durations of Ketoconazole Dosing on the Single‐Dose Pharmacokinetics of Midazolam: Shortening the Paradigm

J. Chodakewitz, J. Wagner, K. Yee, 2009, Journal of clinical pharmacology.

E. Sellers, J. Chodakewitz, J. Wagner, 2012, Journal of Clinical Psychopharmacology.